Tag Archives: BLA

November, 2018

September, 2018

August, 2018

July, 2018

  • 13 July

    Amgen and UCB Resubmit BLA for Evenity to the FDA for the Treatment of Osteoporosis

    THOUSAND OAKS, Calif. and BRUSSELS, July 12, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the resubmission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY™* (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY increases bone …

May, 2018

April, 2018

January, 2018